benralizumab-话题@MedSci

#benralizumab#

7篇内容 | 1182人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2212097, encodeId=3bda221209e77, content=<a href='/topic/show?id=48524024105' target=_blank style='color:#2F92EE;'>#嗜酸性粒细胞性食管炎#</a> <a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=NEJM：Benralizumab治疗12-65岁嗜酸性粒细胞性食管炎，组织学反应率达87.4%, objectType=article, longId=832222, objectId=c77383222242, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719554907505_4754896.png, objectUrl=/article/show_article.do?id=c77383222242, replyNumber=0, likeNumber=70, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c77383222242, moduleTitle=NEJM：Benralizumab治疗12-65岁嗜酸性粒细胞性食管炎，组织学反应率达87.4%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77383222242)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1631034, encodeId=dedf163103411, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=J Allergy Clin Immunol：Benralizumab用于重度嗜酸性粒细胞哮喘青少年患者的3年疗效和安全性, objectType=article, longId=207464, objectId=55b420e464fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55b420e464fa, replyNumber=0, likeNumber=95, createdTime=2021-02-24, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55b420e464fa, moduleTitle=J Allergy Clin Immunol：Benralizumab用于重度嗜酸性粒细胞哮喘青少年患者的3年疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b420e464fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631033, encodeId=d1f616310335e, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=Lancet respir med：嗜酸性粒细胞计数高的COPD患者可获得较好的Benralizumab治疗效果, objectType=article, longId=180286, objectId=84fc18028619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84fc18028619, replyNumber=0, likeNumber=91, createdTime=2019-10-01, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84fc18028619, moduleTitle=Lancet respir med：嗜酸性粒细胞计数高的COPD患者可获得较好的Benralizumab治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84fc18028619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631032, encodeId=c407163103201, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=NEJM：Benralizumab预防COPD恶化, objectType=article, longId=179367, objectId=75ad1e936783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75ad1e936783, replyNumber=0, likeNumber=90, createdTime=2019-09-14, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75ad1e936783, moduleTitle=NEJM：Benralizumab预防COPD恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75ad1e936783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631031, encodeId=fba51631031d5, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=NEJM：Benralizumab可减少重症哮喘患者口服激素的用量, objectType=article, longId=102965, objectId=fa3410296566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa3410296566, replyNumber=0, likeNumber=89, createdTime=2017-06-24, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa3410296566, moduleTitle=NEJM：Benralizumab可减少重症哮喘患者口服激素的用量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa3410296566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631030, encodeId=e6a31631030ef, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=NEJM：对于重症哮喘，benralizumab能有效减轻糖皮质激素依赖, objectType=article, longId=99537, objectId=03c19953e69, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03c19953e69, replyNumber=0, likeNumber=77, createdTime=2017-05-25, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03c19953e69, moduleTitle=NEJM：对于重症哮喘，benralizumab能有效减轻糖皮质激素依赖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03c19953e69)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631029, encodeId=41cf163102990, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功, objectType=article, longId=77044, objectId=8f4ee7044a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f4ee7044a1, replyNumber=0, likeNumber=78, createdTime=2016-09-10, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f4ee7044a1, moduleTitle=喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f4ee7044a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631028, encodeId=dc17163102811, content=<a href='/topic/show?id=95e8334322' target=_blank style='color:#2F92EE;'>#benralizumab#</a>, objectTitle=Lancet：Benralizumab可安全有效治疗病情不受控制的重度哮喘患者（SIROCCO）, objectType=article, longId=76696, objectId=ddb3e669610, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb3e669610, replyNumber=0, likeNumber=76, createdTime=2016-09-07, rootId=0, userName=jwf_2008, userId=d1cd21650045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb3e669610, moduleTitle=Lancet：Benralizumab可安全有效治疗病情不受控制的重度哮喘患者（SIROCCO）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb3e669610)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

benralizumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#嗜酸性粒细胞性食管炎# #benralizumab#

NEJM：Benralizumab治疗12-65岁嗜酸性粒细胞性食管炎，组织学反应率达87.4%

2024-06-28发表于威斯康星

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

J Allergy Clin Immunol：Benralizumab用于重度嗜酸性粒细胞哮喘青少年患者的3年疗效和安全性

2021-02-24

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

Lancet respir med：嗜酸性粒细胞计数高的COPD患者可获得较好的Benralizumab治疗效果

2019-10-01

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

NEJM：Benralizumab预防COPD恶化

2019-09-14

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

NEJM：Benralizumab可减少重症哮喘患者口服激素的用量

2017-06-24

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

NEJM：对于重症哮喘，benralizumab能有效减轻糖皮质激素依赖

2017-05-25

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功

2016-09-10

jwf_2008 (审核中...)

前往app查看评论内容

#benralizumab#

Lancet：Benralizumab可安全有效治疗病情不受控制的重度哮喘患者（SIROCCO）

2016-09-07

科室
- - 订阅+
  - 更多科室
工具
服务